Montgomery County's Globus Medical has agreed to acquire a California life sciences company focused on treating chronic pain ...
Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Labcorp Holdings (LH – Research Report), ...
Canaccord Genuity maintained a Buy rating with a $101.00 price target for Globus Medical (NYSE:GMED) shares, which currently trades at $88.54. The firm's analysis supports the company's ongoing ...
Stock analysts at Roth Capital dropped their FY2024 earnings per share (EPS) estimates for shares of Globus Medical in a ...
Learn more about whether Globus Medical, Inc. or Smith & Nephew plc is a better investment based on AAII's A+ Investor grades ...
BofA analyst Craig Bijou upgraded Globus Medical (GMED) to Neutral from Underperform with a price target of $97, up from $80, after the company preannounced Q4 revenue that was 3% above the Street ...
BTIG says Globus Medical’s (GMED) announced acquisition of Nevro (NVRO) “is surprising on the surface.” Investors did not expect Globus would ...